{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:36:05Z","timestamp":1790141765020,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG09069"],"award-info":[{"award-number":["01KG09069"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12888-019-2014-x","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T14:04:46Z","timestamp":1547474686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-6207","authenticated-orcid":false,"given":"Nadine","family":"Dreim\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter F.","family":"Braus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Elsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Tadi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"2014_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.4088\/JCP.v64n1211","volume":"64","author":"PE Greenberg","year":"2003","unstructured":"Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465\u201375.","journal-title":"J Clin Psychiatry"},{"key":"2014_CR2","doi-asserted-by":"publisher","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","volume":"10","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T, Whiteford HA. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.","journal-title":"PLoS Med"},{"key":"2014_CR3","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, B P, Demler O, Jin R, Koretz D, Merikangas KR. al e: National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095\u2013105.","journal-title":"JAMA"},{"key":"2014_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study C","year":"2015","unstructured":"Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800.","journal-title":"Lancet"},{"key":"2014_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Neuropsychopharmacology. 2011;21:655\u201379.","journal-title":"Neuropsychopharmacology"},{"key":"2014_CR6","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197\u2013223.","journal-title":"Lancet"},{"key":"2014_CR7","first-page":"87","volume":"9","author":"P Sobocki","year":"2006","unstructured":"Sobocki P, J\u00f6nsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econonomics. 2006;9:87\u201398.","journal-title":"J Ment Health Policy Econonomics"},{"key":"2014_CR8","doi-asserted-by":"publisher","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7 .","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"2014_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"2014_CR10","unstructured":"PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder Third Edition."},{"key":"2014_CR11","unstructured":"S3-Leitlinie\/Nationale VersorgungsLeitlinie Unipolare Depression 2. Auflage AWMF-Register-Nr.: nvl-005."},{"key":"2014_CR12","unstructured":"Depression in Adults: Recognition and Management\u2014NICE Guidelines [CG90]. [ http:\/\/www.nice.org.uk\/guidance\/cg90 ]."},{"key":"2014_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4088\/JCP.v66n0201","volume":"66","author":"MA Posternak","year":"2005","unstructured":"Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66:148\u201358.","journal-title":"J Clin Psychiatry"},{"key":"2014_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4088\/JCP.v68n0805","volume":"68","author":"HH Stassen","year":"2007","unstructured":"Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2484 patients. J Clin Psychiatry. 2007;68:1195\u2013205.","journal-title":"J Clin Psychiatry"},{"key":"2014_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpsychires.2017.07.003","volume":"94","author":"S Wagner","year":"2017","unstructured":"Wagner S, Engel A, Engelmann J, Herzog D, Dreimuller N, Muller MB, Tadic A, Lieb K. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis. J Psychiatr Res. 2017;94:96\u2013106.","journal-title":"J Psychiatr Res"},{"key":"2014_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mpr.79","volume":"9","author":"AJ Rush","year":"2000","unstructured":"Rush AJ, Carmody T, Reimitz PE. The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res. 2000;9:45\u201359.","journal-title":"Int J Methods Psychiatr Res"},{"key":"2014_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2014_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.euroneuro.2016.02.003","volume":"26","author":"A Tadic","year":"2016","unstructured":"Tadic A, Wachtlin D, Berger M, Braus DF, van Calker D, Dahmen N, Dreimuller N, Engel A, Gorbulev S, Helmreich I, et al. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--the EMC trial. Eur Neuropsychopharmacol. 2016;26:705\u201316.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2014_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jad.2011.05.025","volume":"139","author":"H Baumeister","year":"2012","unstructured":"Baumeister H, Parker G. Meta-review of depressive subtyping models. J Affect Disord. 2012;139:126\u201340.","journal-title":"J Affect Disord"},{"key":"2014_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0006-3223(96)00440-4","volume":"42","author":"M Fava","year":"1997","unstructured":"Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42:568\u201376.","journal-title":"Biol Psychiatry"},{"key":"2014_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","volume":"165","author":"M Fava","year":"2008","unstructured":"Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, et al. Difference in treatment outcome in outpatients with anxious versus Nonaxious depression: a Star*D report. Am J Psychiatry. 2008;165:342\u201351.","journal-title":"Am J Psychiatry"},{"key":"2014_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/YIC.0b013e328343ba08","volume":"26","author":"S Bitran","year":"2011","unstructured":"Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D. Do early changes in the HAM-D-17 anxiety\/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int Clin Psychopharmacol. 2011;26:206\u201312.","journal-title":"Int Clin Psychopharmacol"},{"key":"2014_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/11588800-000000000-00000","volume":"31","author":"ED Nasso","year":"2011","unstructured":"Nasso ED, Chiesa A, De Ronchi D, Mencacci C. Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. Clin Drug Investig. 2011;31:385\u2013405.","journal-title":"Clin Drug Investig"},{"key":"2014_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jad.2017.06.042","volume":"221","author":"S Wagner","year":"2017","unstructured":"Wagner S, Tadic A, Roll SC, Engel A, Dreimuller N, Engelmann J, Lieb K. A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with major depressive disorders. J Affect Disord. 2017;221:184\u201391.","journal-title":"J Affect Disord"},{"key":"2014_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1176\/appi.ajp.2015.14020181","volume":"172","author":"BA Arnow","year":"2015","unstructured":"Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172:743\u201350.","journal-title":"Am J Psychiatry"},{"key":"2014_CR26","doi-asserted-by":"publisher","unstructured":"Tadi\u0107 A, Gorbulev S, Dahmen N, et al. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder - the EMC trial. Trials. 2010;11:21. https:\/\/doi.org\/10.1186\/1745-6215-11-21 .","DOI":"10.1186\/1745-6215-11-21"},{"key":"2014_CR27","volume-title":"Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV)","author":"APA","year":"1994","unstructured":"APA. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington DC: American Psychiatric Association; 1994."},{"key":"2014_CR28","first-page":"195","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:195\u2013235.","journal-title":"J Clin Psychiatry"},{"key":"2014_CR29","volume-title":"Strukturiertes Klinisches Interview f\u00fcr DSM-IV, Achse II (SKID-II). G\u00f6ttingen","author":"T Fydrich","year":"1997","unstructured":"Fydrich T, Renneberg B, Schmitz B, Wittchen HU. Strukturiertes Klinisches Interview f\u00fcr DSM-IV, Achse II (SKID-II). G\u00f6ttingen. Germany: Hogrefe; 1997."},{"key":"2014_CR30","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","volume":"16","author":"BS Linn","year":"1968","unstructured":"Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"2014_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000318162","volume":"44","author":"S Wagner","year":"2011","unstructured":"Wagner S, Helmreich I, Lieb K, Tadi\u0107 A. Standardized rater training for the Hamilton depression rating scale (HAMD17) and the inventory of depressive symptoms (IDS-C30). Psychopathology. 2011;44:68\u201370.","journal-title":"Psychopathology"},{"key":"2014_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/2153-3539.91130","volume":"2","author":"K Lesack","year":"2011","unstructured":"Lesack K, Naugler C. An open-source software program for performing Bonferroni and related corrections for multiple comparisons. J Pathol Inform. 2011;2:52.","journal-title":"J Pathol Inform"},{"key":"2014_CR33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.psychres.2015.11.009","volume":"238","author":"CH Lin","year":"2016","unstructured":"Lin CH, Huang CJ, Liu SK. Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes. Psychiatry Res. 2016;238:368\u201373.","journal-title":"Psychiatry Res"},{"key":"2014_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","volume":"65","author":"AJ Rush","year":"2008","unstructured":"Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65:870\u201380.","journal-title":"Arch Gen Psychiatry"},{"key":"2014_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2011.04.032","volume":"133","author":"WV Bobo","year":"2011","unstructured":"Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011;133:467\u201376.","journal-title":"J Affect Disord"},{"key":"2014_CR36","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.4088\/JCP.v69n1201","volume":"69","author":"PJ McGrath","year":"2008","unstructured":"McGrath PJ, Khan AY, Trivedi MH, Stewart JW, Morris DW, Wisniewski SR, Miyahara S, Nierenberg AA, Fava M, Rush AJ. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry. 2008;69:1847\u201355.","journal-title":"J Clin Psychiatry"},{"key":"2014_CR37","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.2147\/NDT.S147317","volume":"13","author":"D Lojko","year":"2017","unstructured":"Lojko D, Rybakowski JK. Atypical depression: current perspectives. Neuropsychiatr Dis Treat. 2017;13:2447\u201356.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2014_CR38","doi-asserted-by":"crossref","unstructured":"Gili M, Roca M, Armengol S, Asensio D, Garcia-Campayo J, Parker G: Clinical patterns and treatment outcome in patients with melancholic, atypical and non-melancholic depressions. In PLoS One, vol. 7, 2012\/10\/31 edition. pp. e48200; 2012:e48200.","DOI":"10.1371\/journal.pone.0048200"},{"key":"2014_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jad.2011.02.014","volume":"132","author":"R Uher","year":"2011","unstructured":"Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, et al. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord. 2011;132:112\u201320.","journal-title":"J Affect Disord"},{"key":"2014_CR40","first-page":"15","volume":"13","author":"JW Stewart","year":"2010","unstructured":"Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, Nierenberg AA, Trivedi MH, Balasubramani GK, Warden D, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int Clin Psychopharmacol. 2010;13:15\u201330.","journal-title":"Int Clin Psychopharmacol"},{"key":"2014_CR41","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1017\/S0033291712001742","volume":"43","author":"SC Sung","year":"2013","unstructured":"Sung SC, Wisniewski SR, Balasubramani GK, Zisook S, Kurian B, Warden D, Trivedi MH, Rush AJ. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol Med. 2013;43:945\u201360.","journal-title":"Psychol Med"},{"key":"2014_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00406-017-0798-6","volume":"267","author":"DP Herzog","year":"2017","unstructured":"Herzog DP, Wagner S, Ruckes C, Tadic A, Roll SC, Harter M, Lieb K. Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017;267:711\u201321.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2014_CR43","doi-asserted-by":"crossref","unstructured":"Bschor T, Kern H, Henssler J, Baethge C: Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. In J Clin Psychiatry, vol. 79, 2016\/12\/09 edition; 2018.","DOI":"10.4088\/JCP.16r10749"},{"key":"2014_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/nedt.1.1.51.52298","volume":"1","author":"MH Trivedi","year":"2005","unstructured":"Trivedi MH, Morris DW, Pan JY, Grannemann BD, John Rush A. What moderator characteristics are associated with better prognosis for depression? Neuropsychiatr Dis Treat. 2005;1:51\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2014_CR45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.31887\/DCNS.2008.10.4\/gipapakostas","volume":"10","author":"GI Papakostas","year":"2008","unstructured":"Papakostas GI, Fava M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2008;10:439\u201351.","journal-title":"Dialogues Clin Neurosci"},{"key":"2014_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.euroneuro.2012.02.006","volume":"22","author":"A Schosser","year":"2012","unstructured":"Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S. European Group for the Study of resistant depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453\u201368.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2014_CR47","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s40265-017-0819-9","volume":"77","author":"G Voegeli","year":"2017","unstructured":"Voegeli G, Clery-Melin ML, Ramoz N, Gorwood P. Progress in elucidating biomarkers of antidepressant pharmacological treatment response: a systematic review and meta-analysis of the last 15 years. Drugs. 2017;77:1967\u201386.","journal-title":"Drugs"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2014-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T12:44:33Z","timestamp":1606049073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2014"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2014-x","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was approved in July 2009 by the ethics committee at the Landes\u00e4rztekammer Rheinland-Pfalz (code: 837.211.09 (6717)) and the German Federal Institute for Drugs and Medical Devices (BfArM) approved the trial protocol. All study participants provided written informed consent at enrollment into the protocol treatment. The study was conducted in accordance with the Helsinki Declaration and is compliant with the CONSORT guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AT has received consultancy fees from Janssen and Novartis. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"24"}}